Cytogen싸이토젠
217330 · KOSDAQ · ₩217330 · 싸이토젠
₩2,475▲ ₩25 (1.02%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩26B | ₩11B | ₩3.2B | ₩761M | ₩348M |
| Cost of sales | ₩20B | ₩8.1B | ₩2.3B | ₩566M | ₩291M |
| Gross profit | ₩5.6B | ₩2.8B | ₩846M | ₩195M | ₩57M |
| Operating income | −₩8.2B | −₩11B | −₩12B | −₩11B | −₩13B |
| Net income | −₩12B | −₩17B | −₩16B | −₩19B | −₩11B |
| Net income to shareholders | −₩12B | −₩17B | −₩16B | −₩19B | −₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩62B | ₩72B | ₩74B | ₩41B | ₩56B |
| Current assets | ₩43B | ₩48B | ₩56B | ₩19B | ₩44B |
| Cash and equivalents | ₩11B | ₩31B | ₩55B | ₩16B | ₩30B |
| Total liabilities | ₩26B | ₩24B | ₩21B | ₩36B | ₩33B |
| Current liabilities | ₩15B | ₩4.7B | ₩11B | ₩34B | ₩6.8B |
| Borrowings | ₩15B | ₩14B | ₩16B | ₩26B | ₩24B |
| Total equity | ₩36B | ₩49B | ₩53B | ₩5.7B | ₩23B |
| Shareholders' equity | ₩36B | ₩49B | ₩53B | ₩5.7B | ₩23B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩7B | −₩9.5B | −₩7.6B | −₩6.4B | −₩5.2B |
| Capital spending | ₩2B | ₩1B | ₩2.5B | ₩646M | ₩1.2B |
| Free cash flow | −₩8.9B | −₩11B | −₩10B | −₩7B | −₩6.4B |
Consolidated where available. Amounts in won.
Also known as: Cytogen / 싸이토젠 / 217330 / KRX:217330
Source: KRX statistical information